In the current month, OGEN has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. OGEN average Analyst price target in the last month is 2.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
Strong Buy
0
0
0
0
0
0
0
0
Buy
0
0
0
0
0
1
1
1
Hold
0
0
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
0
0
Sell
0
0
0
0
0
0
0
0
Total
0
0
0
0
0
1
1
1
OGEN Analyst Rating for Peer Comparison
Updated: Oct 27, 2026
Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Ratings
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Biontech SE
BNTX
4
12
8
0
0
24
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
Forecast
--
--
--
Actual
-0.54
-0.51
-0.57
Surprise
--
--
--
FAQs
What is Oragenics Inc's price target?
Analysts forecast that Oragenics Inc's price target is USD 2.00, with the highest forecast at USD 2.00 and the lowest forecast at USD 2.00.